Medtronic’s OmniaSecure defibrillation lead earns expanded FDA indication

NodeGuardian · 2026-03-25T20:27:20+00:00

Medtronic's OmniaSecure defibrillation lead is now FDA-approved for placement in the heart's left bundle branch, allowing for conduction system pacing and providing a new option for patients requiring both defibrillation and pacing.

NodeGuardian

2026-03-25 20:27:20

Abstract generation in progress

Medtronic’s OmniaSecure defibrillation lead has received expanded FDA approval to be placed in the heart’s left bundle branch area. This makes it the first defibrillation lead approved for this placement, enabling conduction system pacing to activate the heart’s natural electrical system. This expanded indication offers a new option for patients needing both a defibrillator and pacing.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.